An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting
Biotechnology and Bioengineering · 2024
DOI: 10.1002/bit.28790 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2024. Written by Gerald M Cherf and 6 co-authors. Institution: Department of Bioengineering, Stanford University, Stanford, California, USA. Major MEDLINE topics: Receptors, Urokinase Plasminogen Activator. Cited 1 times so far (Crossref); 60 references.
Abstract (original language)
Urokinase‐type plasminogen activator receptor (uPAR) is overexpressed on tumor cells in multiple types of cancer and contributes to disease progression and metastasis. In this work, we engineered a novel bi‐paratopic uPAR targeting agent by fusing the binding domains of two native uPAR ligands: uPA and vitronectin, with a flexible peptide linker. The linker length was optimized to facilitate simultaneous engagement of both domains to their adjacent epitopes on uPAR, resulting in a high affinity and avid binding interaction. Furthermore, the individual domains were affinity‐matured using yeast surface display and directed evolution, resulting in a bi‐paratopic protein with affinity in the picomolar to femtomolar range. This engineered uPAR targeting agent demonstrated significantly enhanced tumor localization in mouse tumor models compared to the native uPAR ligand and warrants further investigation as a diagnostic and therapeutic agent for cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Bioengineering, Stanford University, Stanford, California, USA.
- Department of Chemical Engineering, Stanford University, Stanford, California, USA.
- Stanford Cancer Institute, Stanford University, Stanford, California, USA.
ORCID profiles: Jennifer R Cochran
Cite
APA
Cherf, G. M., Lee, R. B., Mehta, N., Clifford, C., Torres, K., Kintzing, J. R., & Cochran, J. R. (2024). An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28790
Vancouver
Cherf GM, Lee RB, Mehta N, Clifford C, Torres K, Kintzing JR, et al. An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28790
BibTeX
@article{Cherf2024,
author = {Cherf, Gerald M and Lee, Robert B and Mehta, Nishant and Clifford, Claire and Torres, Kathleen and Kintzing, James R and Cochran, Jennifer R},
title = {An engineered ultrahigh affinity bi‐paratopic uPAR targeting agent confers enhanced tumor targeting},
journal = {Biotechnology and Bioengineering},
year = {2024},
doi = {10.1002/bit.28790}
}
EUVIMED